Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases. It develops its antibody product candidates to treat cancer and autoimmune diseases. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; AIMab7195, which is in development and commercialization stage. Its product candidates also comprise XmAb14045, a bispecific antibody which is in Phase I clinical trial for the treatment of acute myeloid leukemia; plamotamab (XmAb13676) that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers Tafasitamab, an antibody drug candidate for the treatment of patients with relapsed/refractory diffuse; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG509, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104 which are in preclinical Phase. Additionally, it offers XmAb24306, initial cytokine candidate which is in Phase I clinical trial. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; Amgen Inc.; and Catalent Pharma Solutions LLC., as well as a clinical collaboration with MorphoSys AG and Incyte Corporation to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.
Aware, Inc. provides software and services for the biometrics industry in the United States, the United Kingdom, Brazil, and internationally. It offers biometrics software products, including biometric search and matching software development kits (SDKs), biometric enrollment SDKs and application program interfaces (APIs), identity text analytics SDK A Inquire, biometric services platform A BioSP, and cluster-based matching platform A Astra; and integrated solutions comprising Knomi, AwareABIS, WebEnroll, and Indigo, as well as biometric applications that enable various functions in biometrics systems, such as enrollment, analysis, and processing of biometric images and data on workstations or mobile devices; integration of peripheral biometric capture devices; centralized workflow, transaction processing, and subsystem integration; matching of biometric samples against biometric databases to authenticate or verify identities; and analysis and processing of text-based identity data. The company also provides imaging products for medical applications, such as JPEG2000 product to compress, store, and display images, as well as software maintenance services. In addition, it offers software engineering services comprising project planning and management; system design; software design, development, customization, configuration, and testing; and software integration and installation. The company's software products are used in government and commercial biometrics systems to identify or authenticate people. It sells its biometrics software products and services through systems integrators, OEMs, value added resellers, and directly to end user customers. Aware, Inc. was founded in 1986 and is headquartered in Bedford, Massachusetts.